



A31304 B-A-A 069906.0143

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Mitchell et al.

Serial No.

09/756,095

Examiner

To Be Assigned

Filed

January 8, 2001

Group Art Unit:

1638

For

METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME

MEDIATED RNA TRANS-SPLICING

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.

March 19, 2004

Carmella L. Stephens

41,328

Attorney Name

PTO Registration No

Curmula L. Stephens

March 19, 2004

Signature

Date of Signature

Commissioner for Patents Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the documents listed below in reverse chronological order and on the accompanying PTO 1449 be considered by the Examiner and made of record in the above-referenced application. Copies of the documents listed are enclosed.

03/24/2004 WABRHAM1 00000103 09756095

01 FC:1806

180.00 OP

- 1. United States Patent Application Serial No. 10/434,727, filed May 8, 2003, "Use of spliceosome-mediated RNA trans-splicing to confer cell selective replication to adenoviruses," Otto, E.
- 2. United States Patent Application Serial No. 10/374,784, filed February 25, 2003, "Trans-splicing mediated imaging of gene expression," Mitchell et al.
- 3. United States Patent Application Serial No. 10/198,447, filed July 17, 2002, "Spliceosome mediated RNA trans-splicing for correction of skin disorders," Mitchell et al.
- 4. United States Patent Application Serial No. 10/136,723, filed April 30, 2002, "Transgenic Animal Model for Spliceosome-mediated RNa trans-splicing," Puttaraju et al.
- United States Patent Application Serial No. 10/103,294, filed March 30, 2002,"Spliceosome mediated RNA trans-splicing," Mitchell et al.
- 6. United States Patent Application Serial No. 10/075,028, filed March 12, 2002, "Method and compositions for use in spliceosome mediated RNA trans-splicing," Mitchell et al.
- 7. United States Patent Application Serial No. 10/076,248, filed February 12, 2002, "Method and compositions for use in spliceosome mediated RNA trans-splicing," Mitchell et al.
- 8. United States Patent Application Serial No. 10/941,492, filed August 29, 2001, "Method and compositions for use in spliceosome mediated RNA trans-splicing," Mitchell et al.
- 9. United States Patent Application Serial No. 09/838,858, filed April 20, 2001, "Method and compositions for use in spliceosome mediated RNA trans-splicing," Mitchell et al.
- 10. United States Patent No. 6,280,978, filed Sept. 23, 1998, issued August 28, 2001, "Method and compositions for use in spliceosome mediated RNA trans-splicing," Mitchell et al.
- United States Patent Application Serial No. 09/756,096, filed Jan. 8, 2001,"Method and compositions for use in spliceosome mediated RNA trans-splicing," Mitchell et al.

- 12. United States Patent Application Serial No. 09/756,097, filed Jan. 8, 2001, "Method and compositions for use in spliceosome mediated RNA trans-splicing in plants," Mitchell et al.
- 13. United States Patent No. 6,083,702, filed Aug. 13, 1998, issued July 4, 2000, "Method and compositions for use in spliceosome mediated RNA trans-splicing," Mitchell et al.
- 14. United States Patent No. 6,013,487, filed Dec. 13, 1996, issued Jan. 11, 2000, "Chimeric RNA molecules generated by trans-splicing," of Lloyd Mitchell.
- 15. Mansfield et al., 2000, "Repair of CFTR mRNA by splicesome-mediated RNA trans-splicing," Gene Therapy 7:1885-1895.
- 16. Lan N *et al.*, 1998, "Ribozyme-mediated Repair of Sickle β-Globin mRNAs in Erythrocyte Precursors" *Science* 280:1593-1596.
- 17. Phylactou LA *et al.*, 1998, "Ribozyme-mediated trans-splicing of a trinucleotide repeat" *Nature Genetics* 18:378-381.
- 18. Staley JP *et al.*, 1998, "Mechanical Devices of the Spliceosome: Motors, Clocks, Springs and Things" *Cell* 92:315-326.
- 19. Bellet et al., 1997, "Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin β genes normally transcribed introphoblastic cells," Cancer Res. 57:516.
- 20. Coolidge et al., 1997, "Functional analysis of the polypyrimidine tract in premRNA splicing," Nucleic Acids Res. 25:888.
- 21. Malek O et al., 1997, "Evolution of trans-splicing plant mitochondrial introns in pre-Permian times" *Proc. Nat'l. Acad. Sci. USA* 94:553-558.

- 22. Hoon et al., 1996, "Detection of metastatic breast cancer by β-hCG polymerase chain reaction," Int J. Cancer 69:369.
- 23. Jones JT *et al.*, 1996, "Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells" *Nature Medicine* 2:643-648.
- 24. Krämer A, 1996, "The structure and function of proteins involved in mammalian Pre-mRNA splicing" *Annu. Rev. Biochem.* 65:367-404.
- 25. Nisson, 1996, "Multiple affinity domains for the detection, purification, and immobilization of recombinant proteins," J. et al. J. Mol. Recognit., 1996, 5:585-594.
- 26. Pasman Z et al., 1996, "The 5' and 3' splice sites come together via a three dimensional diffusion mechanism" *Nucleic Acids Res.* 24(9):1638-1645.
- 27. Bruzik JP *et al.*, 1995, "Enhancer-dependent interaction between 5' and 3' splice sites in trans" *Proc. Nat'l. Acad. Sci. USA* 92:7056-7059.
- 28. Chiara MD *et al.*, 1995, A two-step mechanism for 5' and 3' splice-site pairing" *Nature* 375:510-513.
- 29. Davis RE et al., 1995, "RNA Trans-splicing in Flatworms" J. Biol. Chem. 270:21813-21819.
- 30. Eul J *et al.*, 1995, "Experimental evidence for RNA trans-splicing in mammalian cells: *EMBO. J.* 14(13):3226-3235.
- 31. Hollenberg et al., 1994, "Multiple promoter elements in the human chorionic gonadotropin b subunit genes distinguish their expression from luteinizing hormone β gene," Mol. Cell Endo., 106:111-119.
- 32. Sullenger BA *et al.*, 1994, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing" *Nature* 341:619-622.

- 33. Goldspiel et al., 1993, "Human gene therapy," Clinical Pharmacy 12:488-505.
- 34. Kozarsky and Wilson, 1993, "Gene therapy:adenovirus vectors," Current Opinion in Genetics and Development 3:499-503.
- 35. Miller *et al.*, 1993, "Use of adenoviral vectors for gene transfer and expression," Meth. Enzymol. 217:581-599.
- 36. Moore and Sharp, 1993, "Evidence for two active sites in the splicesome provided by sterochemistry of pre-mRNA splicing," Nature, 365:364-368.
- 37. Moore, 1993, "Splicing of precursors to mRNA by the spliceosome," in RNA World, R.F. Gesteland and J.F. Atkins, eds. Cold Spring Harbor Laboratory Press, p303-358.
- 38. Morgan and Anderson, 1993, "Human Gene Therapy," Ann. Rev. Biochem. 62:191-217.
 - 39. Mulligan, 1993, "The basic science of gene therapy," Science 260:926-932.
- 40. Roscigno et al., 1993, "A mutational analysis of the polypyrimidine tract of introns," J. Bio. Chem., 268:11222-11229.
- 41. Tolstoshev, 1993, "Gene therapy, concepts, current trials, and future directions," Ann. Rev. Pharmacol. Toxicol. 33:573-596.
- 42. Acevedo et al., 1992, "Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins," Cancer 76:1467.
- 43. Bruzik JP *et al.*, 1992, "Spliced leader RNAs from lower eukaryotes are transspliced in mammalian cells: *Nature* 360:692-695.
- 44. Vellard M *et al.*, 1992, "A potential splicing factor is encoded by the opposite strand of the trans-spliced c-myb exon" *Proc. Nat'l. Acad. Sci.*, 89:2511-2515.

- 45. Janknecht et al., 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus," Proc. Natl. Acad. Sci., 88:8972-8976.
 - 46. Wu and Wu, 1991, "Delivery systems for gene therapy," Biotherapy 3:87-95
 - 47. United States Patent No. 4,980,286, issued Dec. 25, 1990 of Morgan et al.
- 48. Rajkovic A *et al.*, 1990, "A spliced leader is present on a subset of mRNAs from the human parasite *Schistosoma mansoni*" *Proc. Nat'l. Acad. Sci. USA*, 87:8879-8883.
- 49. Schneider et al., 1990, "Building blocks for oligonucleotide analogs with dimethyl-sulfide-sulfoxide and sulfone groups replacing phosphodiester linkages," Tet. Letters, 31:335.
- 50. Senapathy et al., 1990, "Splice junctions, branch point sites, and exons:sequence statistics, identification, and applications to genome project," Methods of Enzymology, 183:252-278.
- 51. Uhlmann et al., 1990, "Antisense oligonucleotides:a new therapeutic principle," Chem Rev., 90:543-549.
- 52. International Patent Application No. PCT/US89/01589 of, published on November 2, 1989 as International Publication No. WO89/10134.
- 53. Kerem et al., 1989, "Identification of the Cystic Fibrosis Gene:Genetic analysis," Science, 245:1073-1080.
- 54. Letsinger et al., 1989, "Cholesterol-conjugated oligonucleotides; synthesis, properties, and activity as inhibitors of replication of human immunodeficiency cirus in cell culture, " Proc. Natl. Acad. Sci., 86:6553-6556
- 55. Reed, 1989, "The organization of 3' splice sites sequences in mammalian introns," Genes Dev. 3:2113.

- 56. Riordan et al., 1989, "Identification of the Cystic Fibrosis Gene:Cloning and characterization of complementary DNA," Science, 245:1066-1073.
- 57. Rommens et al., 1989, "Identification of the Cystic Fibrosis Gene: Chromosome walking and jumping," Science, 245:1059-1065.
- 58. Shimizu A *et al.*, 1989, "Immunoglobulin double-isotype expression by transmRNA in a human immunoglobulin transgenic mouse" *Proc. Nat'l. Acad. Sci. USA* 86:8020-8023.
- 59. Smith et al., 1989, "Scanning from an independently specified branch point defines the 3' splice site of mammalian introns," Nature, 342-243-247.
- 60. International Patent Application No. PCT/US88/02009 of Synthetic Genetics, published on Dec. 15, 1988 as International Publication No. WO88/09810.
- 61. van der Krol et al., 1988, "Modulation of eukaryotic gene expression by complementary RNA or DNA sequences," BioTechniques, 6:958-976.
- 62. Reed & Maniatis 1988, "The role of the mammalian branchpoint sequence in the pre-mRNA splicing," Genes Dev. 2:1268.
- 63. Smith et al, 1988, "Single-step purification of polypepetides expressed in Escherichia coli as fusions with glutathione S-transferase," Gene, 67:31
- 64. Zon et al., 1988, "Oligonucleotide analogues as potential chemotherapeutic agents," Pharm. Res., 5:539-549.
- 65. Krause M et al., 1987, "A Trans-spliced Leader Sequence on Actin mRNA in C. elegans" Cell 49:753-761.

- 66. Lemaitre et al., 1987, "Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site," Proc. Natl. Acad. Sci., 84:648-652.
- 67. Wu and Wu, 1987, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," J. Biol. Chem., 262:429-4432.
- 68. Murphy et al., 1986, "Identification of a novel Y branch structure as an intermediate in Trypanosome m RNA processing: evidence for Trans splicing," Cell, 47:517.
- 69. Smith et al., 1986, "Mr 26,000 antigen of Schistosoma japonica recognized by resistant WEH1 129/J mice is a parasite glutathione S-transferase," Proc. Natl. Acad. Sci., 83:8703-8707.
- 70. Sutton RE *et al.*, 1986, "Evidence for Trans Splicing in Trypanosomes" *Cell* 47:527-535.
- 71. Konarska MM *et al.*, 1985, "Trans Splicing of mRNA Precursors In Vitro" *Cell* 46:165-171.
 - 72. Solnick D, 1985, "Trans Splicing of mRNA Precursors" *Cell* 42:157-164.
- 73. Talmadge et al., 1984, "Only three of the seven chorionic gonadotropin beta subunit genes can be expressed in the placenta," Nucleic Acids Res. 12:8415.
- 74. Accession No. K01722, Corynebacteriophage beta diptheria toxin (DT) gene, 1983.
- 75. Greenfield, 1983, "Nucleotide sequence of the structural gene for the diptheria toxin carried by corynebacteriophage β," Proc. Natl. Acad. Sci., 80:6853-6857.
- 76. Brinster et al., 1982, "Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs," Nature, 296:39-42.

- 77. Benoist et al., 1981, ""In vivo sequence requirements of the SV40 early promoter region," Nature, 290:304-310.
- 78. Wagner TE *et al.*, 1981, "Microinjection of a rabbit β-globin gene into zygotes and its subsequent expression in adult mice and their offspring" *Proc. Natl. Acad. Sci. USA* 78(10):6376-6380.
- 79. Yamamoto et al., 1980, "Identification of a functional promoter in the long terminal repeat of Rous Sarcoma Virus," Cell, 22:39-42.
- 80. Berget SM *et al.*, 1977, "Spliced segments at the 5' terminus of adenovirus 2 late mRNA" *Proc. Natl. Acad. Sci. USA* 74(8):3171-3175.
- 81. Chow LT *et al.*, 1977, "An Amazing Sequence Arrangement at the 5' Ends of Adenovirus 2 Messenger RNA" *Cell* 12:1-8.
- 82. Uchida et al, 1973, "Diptheria toxin and related proteins: isolation and properties of mutant proteins related to diptheria toxin," J. Biol. Chem., 248:3838.

References #1-9, 11, and 12 are related co-pending U.S. patent applications.

Identification of the above-listed citations is not to be construed as an admission of the applicants or attorneys for applicants that such citations are available as "prior art" against the subject application.

MAR 2 4 2004 W

Pursuant to 37 C.F.R. § 1.97(c), this Information Disclosure Statement is

accompanied by the fee set forth in 37 C.F.R. § 1.17(p). However, if any additional fee is required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. A duplicate copy of this paper is enclosed.

Respectfully submitted, BAKER BOTTS L.L.P.

Backella K. Saida

Rochelle K. Seide Patent Office Reg. No. 32,300

Carmella L. Stephens Patent Office Reg. No. 41,328

30 Rockefeller Plaza 44th Floor New York, NY 10112 (212) 408-2500

Attorneys for Applicants

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office					Atty. Docket No. Serial No. A31304BAA 069906.0143 09/756,095									
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Applicant Mitchell et al.									
OIPE (Use several sheets if necessary)							ssar	y)	Filing Date Jan. 8, 2001	Gro	ıp			
MAR	2 4 20	104		•										
W. C. T. C.	U.S. PATENT DOCUMENTS													
*Exa m.		Document No. Date					Date	Name	Class	Subclass	Filing Da			
Init.	10	6	2	8	0	9	7	8	8/28/01	Mitchell et al.	435	91.3		
	13	6	0	8	3	7	0	2	7/4/00	Mitchell et al.	435	6		
	14	6	0	1	3	4	8	7	1/11/00	Mitchell et al.	435	91.3		
	47	4	9	8	0	2	8	6	12/25/90	Morgan et al.	435	1723		
								FO	REIGN PAT	TENT DOCUMENT				
										Translati	_			
	52	8	9	1	ument 0	1	3	4	Date 11/2/89	WIPO	Class	SubClass	Yes	No
	60	8	8	0	9	8	1	0	12/15/88	WIPO				
											-			
			O	ГНЕ	R D	OCU	ME	NTS	(including A	Author, Title Date, Pertinent	t Pages	, Etc.)		
	United States Patent Application Serial No. 10/434,727, filed May 8, 2003, "Use of spliceosome-mediated RNA trans-splicing to confer cell selective replication to adenoviruses," Otto, E.													
	2	United States Patent Application Serial No. 10/374,784, filed February 25, 2003, "Trans-splicing mediated imaging of gene expression," Mitchell et al.												
-	3	United States Patent Application Serial No. 10/198,447, filed July 17, 2002, "Spliceosome mediated RNA trans-splicing for correction of skin disorders," Mitchell et al.												
	4	United States Patent Application Serial No. 10/136,723, filed April 30, 2002, "Transgenic Animal Model for Spliceosome-mediated RNa trans-splicing," Puttaraju et al.												
NY02:452	:507.1									1				
Examir	ner								Date Con	sidered				

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO- (REV. 2-82)	449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. A31304BAA 069906.0143	Serial No. 09/756,095		
INFORM	MATION DISCLOSURE STATEMENT BY APPLICANT	Applicant Mitchell et al.			
2 1 3006	(L)se several sheets if necessary)	Filing Date Jan. 8, 2001	Group		
PIAN 2 4 CO					
RATESAR	United States Patent Application Serial No RNA trans-splicing," Mitchell et al.	o. 10/103,294, filed March 30, 200	2, "Spliceosome mediated		
6	6 United States Patent Application Serial No. 10/075,028, filed March 12, 2002, "Method a for use in spliceosome mediated RNA trans-splicing," Mitchell et al.				
7	United States Patent Application Serial No compositions for use in spliceosome media				
8	1, "Method and compositions				
9	United States Patent Application Serial No for use in spliceosome mediated RNA trans		, "Method and compositions		
11	United States Patent Application Serial No. 09/756,096, filed Jan. 8, 2001, "Method and compositions fo use on spliceosome mediated RNA trans-splicing," Mitchell et al.				
12	United States Patent Application Serial No use in spliceosome mediated RNA trans-sp		Method and compositions for		
15	Mansfield et al., 2000, "Repair of CFTR mRNA by splicesome-mediated RNA trans-sp Therapy 7:1885-1895.				
16	Lan N et al., 1998, "Ribozyme-mediated repair of Sickle β-Globin mRNAs in Erythrocyte Precision Science 280:1593-1596.				
17	Phylactou LA <i>et al.</i> , 1998, "Ribozyme-med 18:378-381.	diated trans-splicing of a trinucleo	tide repeat" Nature Genetics		
18	Staley JP <i>et al.</i> , 1998, "Mechanical Device 92:315-326.	es of the Spliceosome: Motors, Clo	ocks, Springs and Things" Cel		
NY02:452507.1		2			
Examiner	Date Con	sidered	-		

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3 3						
Form PTC (REV. 2-82		Department of Commerce nd Trademark Office	Atty. Docket No. A31304BAA 069906.0143	Serial No. 09/756,095		
	B	DISCLOSURE STATEMENT Y APPLICANT	Applicant Mitchell et al.			
MAR 2. 4 2004	Use seve	eral sheets if necessary)	Filing Date Jan. 8, 2001	Group		
E BADENAP	1,0					
19		let et al., 1997, "Malignant transformationic gonadotropin β genes normally	•	<u>-</u>		
20		olidge et al., 1997, "Functional analysis ds Res. 25:888.	s of the polypyrimidine tract in pre	e-mRNA splicing," Nucleic		
21		Malek O et al., 1997, "Evolution of trans-splicing plant mitochondrial introns in pre-Permian times" Proc. Nat'l. Acad. Sci. USA 94:553-558.				
22		Hoon et al., 1996, "Detection of metastatic breast cancer by β-hCG polymerase chain reaction," Int J. Cancer 69:369.				
23		Jones JT et al., 1996, "Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells" Natur Medicine 2:643-648.				
24	1 1	Krämer A, 1996, "The structure and function of proteins involved in mammalian Pre-mRNA splicing" Annu. Rev. Biochem. 65:367-404.				
25		Nisson, 1996, "Multiple affinity domains for the detection, purification, and immobilization of recombinan proteins," J. et al. J. Mol. Recognit., 1996, 5:585-594.				
26	Pasi	Pasman Z et al., 1996, "The 5' and 3' splice sites come together via a three dimensional diffusion mechanism" Nucleic Acids Res. 24(9):1638-1645.				
27		Bruzik JP et al., 1995, "Enhancer-dependent interaction between 5' and 3' splice sites in trans" Proc. Nat'l Acad. Sci. USA 92:7056-7059.				
28	Chi	ara MD et al., 1995, "A two-step mech	anism for 5' and 3' splice-site pair	ring" <i>Nature</i> 375:510-513.		
29	Dav	ris RE et al., 1995, "RNA Trans-splicir	ng in Flatworms" J. Biol. Chem. 27	70:21813-21819.		
30		J et al., 1995, "Experimental evidence 13):3226-3235.	for RNA trans-splicing in mamma	alian cells: EMBO. J.		

NY02:452507.1

3

Examiner

Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

a							
	1449 U.S. Department of Comn Patent and Trademark Offic		Atty. Docket No. A31304BAA 069906.0143	Serial No. 09/756,095			
MYBR	MATION DISCLOSURE BY APPLICANT	STATEMENT	Applicant Mitchell et al.				
MAR 2 4 20(4) several sheets if necessary)		essary)	Filing Date Jan. 8, 2001	Group			
RADEN	ENCE						
31	Hollenberg et al., 1994	Hollenberg et al., 1994, "Multiple promoter elements in the human chorionic gonadotropin b subunit genes distinguish their expression from luteinizing hormone β gene," Mol. Cell Endo., 106:111-119.					
32	Sullenger BA et al., 19 Nature 341:619-622.	Sullenger BA <i>et al.</i> , 1994, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing" Nature 341:619-622.					
33	Goldspiel et al., 1993,	Goldspiel et al., 1993, "Human gene therapy," Clinical Pharmacy 12:488-505.					
34		Kozarsky and Wilson, 1993, "Gene therapy:adenovirus vectors," Current Opinion in Genetics and Development 3:499-503.					
35	Miller et al., 1993, "U. 599.	Miller et al., 1993, "Use of adenoviral vectors for gene transfer and expression," Meth. Enzymol. 217:581-599.					
36		Moore and Sharp, 1993, "Evidence for two active sites in the splicesome provided by sterochemistry of pre mRNA splicing," Nature, 365:364-368.					

Moore, 1993, "Splicing of precursors to mRNA by the spliceosome," in RNA World, R.F. Gesteland and

Roscigno et al., 1993, "A mutational analysis of the polypyrimidine tract of introns," J. Bio. Chem.,

Tolstoshev, 1993, "Gene therapy, concepts, current trials, and future directions," Ann. Rev. Pharmacol.

Acevedo et al., 1992, "Human chorionic gonadotropin-beta subunit gene expression in cultured human feta

J.F. Atkins, eds. Cold Spring Harbor Laboratory Press, p303-358.

and cancer cells of different types and origins," Cancer 76:1467.

Mulligan, 1993, "The basic science of gene therapy," Science 260:926-932.

NY02:452507.1

37

38

39

40

41

42

268:11222-11229.

Toxicol. 33:573-596.

4

Morgan and Anderson, 1993, "Human Gene Therapy," Ann. Rev. Biochem. 62:191-217.

Examiner

Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PT (REV. 2-		U.S. Department of Commerce stent and Trademark Office	Atty. Docket No. A31304BAA 069906.0143	Serial No. 09/756,095		
OHNEO	RMAT	TION DISCLOSURE STATEMENT BY APPLICANT	Applicant Mitchell et al.			
MAR 2 4 20	9.1	e several sheets if necessary)	Filing Date Jan. 8, 2001	Group		
) }	A CA					
BADRY	3	Bruzik JP et al., 1992, "Spliced leader RN. Nature 360:692-695.	As from lower eukaryotes are trans	s-spliced in mammalian cells:		
4	4	Vellard M et al., 1992, "A potential splicin myb exon" Proc. Nat'l. Acad. Sci., 89:2511		e strand of the trans-spliced c-		
4	Janknecht et al., 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus," Proc. Natl. Acad. Sci., 88:8972-8976.					
4	Wu and Wu, 1991, "Delivery systems for gene therapy," Biotherapy 3:87-95. 4,980,286, issued Dec. 25, 1990 of Morgan et al.					
4	8	Rajkovic A et al., 1990, "A spliced leader is present on a subset of mRNAs from the human parasite Schistosoma mansoni" Proc. Nat'l. Acad. Sci. USA, 87:8879-8883.				
4	9	Schneider et al., 1990, "Building blocks for oligonucleotide analogs with dimethyl-sulfide-sulfoxide and sulfone groups replacing phosphodiester linkages," Tet. Letters, 31:335.				
50	0	Senapathy et al., 1990, "Splice junctions, branch point sites, and exons:sequence statistics, identification, and applications to genome project," Methods of Enzymology, 183:252-278.				
5	1	Uhlmann et al., 1990, "Antisense oligonucleotides:a new therapeutic principle," Chem Rev., 90:543-549.				
5.	3	Kerem et al., 1989, "Identification of the Cystic Fibrosis Gene:Genetic analysis," Science, 245:1073-1080.				
54	4	Letsinger et al., 1989, "Cholesterol-conjugated oligonucleotides; synthesis, properties, and activity as inhibitors of replication of human immunodeficiency cirus in cell culture, " Proc. Natl. Acad. Sci., 86:6553 6556				
5:	5	Reed, 1989, "The organization of 3' splice sites sequences in mammalian introns," Genes Dev. 3:2113.				
50	6	Riordan et al., 1989, "Identification of the Cystic Fibrosis Gene:Cloning and characterization of complementary DNA," Science, 245:1066-1073.				
NY02:452507	'.1	I	5			

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Examiner

	1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. A31304BAA 069906.0143	Serial No. 09/756,095				
, C.	MATION DISCLOSURE STATEMENT BY APPLICANT	Applicant Mitchell et al.					
MAR 2' 4 2004	(L) se several sheets if necessary)	Filing Date Jan. 8, 2001	Group				
P. BADEMARK	7						
57	Rommens et al., 1989, "Identification of the Science, 245:1059-1065.	ne Cystic Fibrosis Gene: Chromoso	ome walking and jumping,"				
58	Shimizu A et al., 1989, "Immunoglobulin immunoglobulin transgenic mouse" Proc.	double-isotype expression by trans Nat'l. Acad. Sci. USA 86:8020-802	s-mRNA in a human 23.				
59	Smith et al., 1989, "Scannine from an inde mammalian introns," Nature, 342-243-247		lefines the 3' splice site of				
61	van der Krol et al., 1988, "Modulation of e sequences," BioTechniques, 6:958-976.	eukaryotic gene expression by com	plementary RNA or DNA				
62	Reed & Maniatis 1988, "The role of the mammalian branchpoint sequence in the pre-mRNA splicing," Genes Dev. 2:1268.						
63	Smith et al, 1988, "Single-step purification glutathione S-transferase," Gene, 67:31	Smith et al, 1988, "Single-step purification of polypepetides expressed in Escherichia coli as fusions with glutathione S-transferase," Gene, 67:31					
64	Zon et al., 1988, "Oligonucleotide analogues as potential chemotherapeutic agents," Pharm. Res., 5:539-549.						
65	Krause M et al., 1987, "A Trans-spliced Le	Krause M et al., 1987, "A Trans-spliced Leader Sequence on Actin mRNA in C. elegans" Cell 49:753-761					
66	Lemaitre et al., 1987, "Specific antiviral ac sequence complementary to vesicular stom Sci., 84:648-652.	tivity of a poly(L-lysine)-conjugat atitis virus N protein mRNA initia	ed oligodeoxyribonucleotide tion site," Proc. Natl. Acad.				
67	Wu and Wu, 1987, "Receptor-mediated in Biol. Chem., 262:429-4432.	Wu and Wu, 1987, "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," J.					
68	Murphy et al., 1986, "Identification of a novel Y branch structure as an intermediate in Trypanosome m RNA processing:evidence for Trans splicing," Cell, 47:517.						
69	Smith et al., 1986, "Mr 26,000 antigen of S is a parasite glutathione S-transferase," Pro	chistosoma japonica recognized by c. Natl. Acad. Sci., 83:8703-8707.	y resistant WEH1 129/J mice				
NY02:452507.1	t	6					

Date Considered

Examiner

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office

Ally. Docket No.	
A31304BAA	069906.0143

Serial No. 09/756,095

ONFORMATIO	ON DISCLOSUR BY APPLICAN	E STATEMENT
16	BY APPLICAN	T
MAR 2 4 2004 (Use s	everal sheets if no	ecessary)

Applicant
Mitchell et al.

Filing Date
Jan. 8, 2001

Group

CE MADERARY

70	Sutton RE et al., 1986, "Evidence for Trans Splicing in Trypanosomes" Cell 47:527-535.
71	Konarska MM et al., 1985, "Trans Splicing of mRNA Precursors In Vitro" Cell 46:165-171.
72	Solnick D, 1985, "Trans Splicing of mRNA Precursors" Cell 42:157-164.
73	Talmadge et al., 1984, "Only three of the seven chorionic gonadotropin beta subunit genes can be expresse in the placenta," Nucleic Acids Res. 12:8415.
74	Accession No. K01722, Corynebacteriophage beta diptheria toxin (DT) gene, 1983.
75	Greenfield, 1983, "Nucleotide sequence of the structural gene for the diptheria toxin carried by corynebacteriophage β," Proc. Natl. Acad. Sci., 80:6853-6857.
76	Brinster et al., 1982, "Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs," Nature, 296:39-42.
77	Benoist et al., 1981, ""Invivo sequence requirements of the SV40 early promoter region," Nature, 290:304 310.
78	Wagner TE et al., 1981, "Microinjection of a rabbit β-globin gene into zygotes and its subsequent expression in adult mice and their offspring" Proc. Natl. Acad. Sci. USA 78(10):6376-6380.
79	Yamamoto et al., 1980, "Identification of a functional promoter in the lond terminal repeat of Rous Sarcoma Virus," Cell, 22:39-42.
80	Berget SM et al., 1977, "Spliced segments at the 5' terminus of adenovirus 2 late mRNA" Proc. Natl. Acad. Sci. USA 74(8):3171-3175.

NY02:452507.1

7

Examiner

Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(ŖEV. 2-8	32) Pa	itent and Trademark Office	A31304BAA 069906.0143	09/756,095
INFOI PE	RMAT	TION DISCLOSURE STATEMENT BY APPLICANT	Applicant Mitchell et al.	
<u> </u>	189) 13 400	e several sheets if necessary)	Filing Date Jan. 8, 2001	Group
MAR 2 L T	and the			
81	1	Chow LT et al., 1977, "An Amazing Sequ RNA" Cell 12:1-8.	ence Arrangement at the 5' Ends	of Adenovirus 2 Messenger
82	2	Uchida et al, 1973, "Diptheria toxin and re to diptheria toxin," J. Biol. Chem., 248:38:	elated proteins: isolation and prope 38.	erties of mutant proteins related
		-		
NY02:452507.	.1		8	
Examiner		Date Con	sidered	

Atty. Docket No.

Form PTO-1449 U.S. Department of Commerce

Serial No.

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.